![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Wednesday, February 03, 2016 9:05:41 PM
Yet, I don't understand why tonite should be any different then any other nite. Why these new orders? (See Bottom of this post). Is somebody expecting a potential PPHM RUN/BreakOut?
These orders could have been placed as GoodTilCancelled?
Well, all I am trying to say is, I noticed something peculiar and out of the ordinary tonite, and I wanted to post it to the board before it disappeared, for any that might be interested, for what it is worth...
...
thanks for the info and when things change its best to chase after every single lead and see what turns up. I wonder what will turn up with BeiGene, where SA Jedd Wolchok popped up at....and so much secrecy like PPHM
---------------------
Currently we are engaged in partnering/in-licensing discussions related to the following programs:
MEKi
ERKi
PI3K-delta
BCL-2i
IRAK4i
LAG3i
CD-27i
CD-137i
Immuno-modulator inhibitors that are potentially synergistic with PD-1/PD-L1 mAbs
If you would like additional information on partnering with BeiGene, please contact our business development team at bd@beigene.com
http://www.beigene.com/business-development/overview/
---------------------------------
Combination Solutions:
Please read: "ENHANCED BY UNDISCLOSED I-O AGENTS" on the graph in the link below:
http://www.beigene.com/our-science/combination-solutions/
--------------------------------
Scientific Advisory Board
Ron Levy, M.D.
Professor of Medicine, Director of Lymphoma Program, Former Chief of Division of Oncology at Stanford
Member of National Academy of Sciences & Institute of Medicine
More than 20 years research on mAb to B cells; first to successfully treat human lymphoma with a monoclonal antibody, and went on to make important contributions to the development of rituximab (Rituxan®), for treatment of patients with resistant low-grade lymphomas
Neal Rosen, M.D., Ph.D.
Member of Department of Medicine and Head of Developmental Therapeutics at Memorial Sloan-Kettering Cancer Center
Professor of Pharmacology, Cell Biology and Medicine at Cornell University
Played important role in developing tyrosine kinase-mediated signaling inhibitors and pioneered concept that cancer cells are dependent on cellular machinery for protein folding
Charles Sawyers, M.D.
President-elect of the AACR; former President of the American Society of Clinical Investigation
Serves on the National Cancer Institute’s Board of Scientific Counselors
Member of the Institute of Medicine of the National Academy of Sciences
David Schenkein, M.D.
Agios (AGIO) Chief Executive Officer
Adjunct Attending Physician in Hematology at Tufts Medical Center
Member of the board of directors for the Biotechnology Industry Organization (BIO)
Formerly at Genentech, Millennium Pharma
Served as Adjunct Clinical Professor of Medical Oncology at Stanford
Xiaodong Wang, Ph.D.
Founder & Chairman SAB
Director of National Institute of Biological Sciences in Beijing
Former Howard Hughes Investigator, Distinguished Chair of Biomedical Sciences and Professor of Biochemistry at University of Texas-Southwestern
Member of National Academy of Sciences, USA
Founder of Joyant Pharmaceuticals, venture capital-backed oncology biotech in U.S.
Jedd Wolchok, M.D., Ph.D.
Chief of the Melanoma and Immunotherapeutics Service at Memorial Sloan Kettering Cancer Center (MSK)
Associate Director of the Ludwig Center for Cancer Immunotherapy and the Lloyd J. Old/Virginia and Daniel K. Ludwig Chair for Clinical Investigation at MSK
Associate Director of the CRI Scientific Advisory Council
Co-editor of the journal Cytotherapy
M.D. and a Ph.D. from New York University
http://beigeneltd.com/company/scientific-advisory-board/
-------------------------------
SEC Filings:
http://ir.beigene.com/phoenix.zhtml?c=254246&p=irol-sec&secCat01.1_rs=1&secCat01.1_rc=20
------------------------------
I think we are in for an exciting Feb of 2016 that we may not forget
"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical
pipeline." -- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!
Recent CDMO News
- Avid Bioservices Reports Financial Results for Fourth Quarter and Fiscal Year Ended April 30, 2024 • GlobeNewswire Inc. • 07/02/2024 08:05:04 PM
- Avid Bioservices to Report Financial Results for Quarter and Fiscal Year Ended April 30, 2024, After Market Close on July 2, 2024 • GlobeNewswire Inc. • 07/01/2024 11:00:21 AM
- Avid Bioservices Earns Committed Badge from EcoVadis for Sustainability Performance • GlobeNewswire Inc. • 05/23/2024 12:05:46 PM
- Avid Bioservices to Participate at Upcoming Investor Conferences • GlobeNewswire Inc. • 05/07/2024 08:05:11 PM
- Avid Bioservices Reports Financial Results for Third Quarter Ended January 31, 2024 • GlobeNewswire Inc. • 04/24/2024 09:25:33 PM
- Avid Bioservices Announces Receipt of Deficiency Notice from Nasdaq Regarding Late Form 10-Q • GlobeNewswire Inc. • 03/20/2024 11:00:10 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/07/2024 11:30:11 AM
- Avid Bioservices Announces Pricing of Private Placement of Convertible Notes • GlobeNewswire Inc. • 03/07/2024 04:58:48 AM
- Avid Bioservices Announces Proposed Private Placement of Convertible Notes • GlobeNewswire Inc. • 03/06/2024 09:32:07 PM
- Avid Bioservices Announces Certain Preliminary Financial Results for Third Quarter Ended January 31, 2024 • GlobeNewswire Inc. • 03/06/2024 09:31:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2024 09:30:18 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 01/26/2024 09:57:52 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/13/2024 12:34:35 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 12:39:18 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 12:38:30 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 12:37:38 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 12:36:27 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 12:35:47 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/11/2024 12:56:02 AM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 01/08/2024 09:32:36 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 12:56:18 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 12:55:07 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 12:53:58 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 12:51:57 AM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM